Stockwin_Shoemaker 2009
Gene expression profiling of alveolar soft-part sarcoma (ASPS)
Lazar_Lev 2009
Validation of potential therapeutic targets in alveolar soft part
sarcoma: an immunohistochemical study utilizing tissue
microarray
Selvarajah_Flavin 2011
Identification of neural stem cell gene expression signatures associated with
disease progression in alveolar soft part sarcoma by integrated molecular profilin
Kummar_Helman 2013
Cediranib for Metastatic Alveolar Soft Part Sarcoma
Goodwin_Jones 2014
Modeling Alveolar Soft Part Sarcomagenesis
in the Mouse: A Role for Lactate
in the Tumor Microenvironment
Li_Zhang 2022
Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy
Scoffski_Stacchiotti 2018
Activity and safety of crizotinib in patients
with alveolar soft part sarcoma with rearrangement
of TFE3: European Organization for Research
and Treatment of Cancer (EORTC) phase II trial
90101 ‘CREATE’
Chi_Cai 2022
Safety and Efficacy of Anlotinib, a Multikinase
Angiogenesis Inhibitor, in Patients with Refractory
Metastatic Soft-Tissue Sarcoma
Ye_Chai 2018
Effective treatment of advanced alveolar soft part
sarcoma with sunitinib
Wilki_Trent 2019
Axitinib plus pembrolizumab in patients with advanced
sarcomas including alveolar soft-part sarcoma:
a single-centre, single-arm, phase 2 trial